Video

Prevention and Early Detection of Cervical Cancer

Vaccines can protect against human papillomavirus (HPV) infection, a known and necessary causative agent for the development of cervical cancer, anal cancer, and many head and neck cancers, says Thomas Herzog, MD. By including additional valents, protection has increased from almost 70% to more than 85% since vaccines were introduced nearly a decade ago, notes Herzog. Despite its efficacy, uptake with the HPV vaccine has been poor.

Vaccination and screening are part of a 2-tiered approach to cervical cancer prevention, states Bradley J. Monk, MD. Methods of screening include the Papanicolaou (Pap) test and HPV test, the latter of which tests for the virus on the cervix. In general, the HPV test outperforms the Pap test, says Monk.

There has been a lot of stigmatization related to the HPV vaccine, comments Herzog, who would like to see more of a public health initiative to increase its use. Cervical cancer is most prevalent in areas that do not have screening available, adds Robert L. Coleman, MD.

Related Videos
Cedric Pobel, MD
Kathleen N. Moore, MD, MS
Jennifer Scalici, MD
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.